Short answer
Entrada Therapeutics, Inc. (TRDA) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $898,000 (down 53.9% year over year) with net income of −$43M.
Q2 2026 key financials · XBRL
- Revenue
- $898,000
- −53.9% YoY · +2.6% QoQ
- Net income
- −$43M
- +0.8% YoY · −7.7% QoQ
- Operating margin
- -5007.0%
- EPS (diluted)
- −$1.01
- +3.8% YoY · −6.3% QoQ
Source: XBRL data from the Entrada Therapeutics, Inc. (TRDA) Q2 2026 10-Q on SEC EDGAR. USD.
Entrada Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash, equivalents and marketable securities $223.0M as of June 30, 2026
- Cash runway into Q3 2027 based on current operating plans
- ENTR-601-44 dystrophin increase 2.36% to total mean 6.36%
- ENTR-601-44 exon skipping increase 2.31% to total mean 4.97%
- Cohort 2 ENTR-601-44 topline results expected Q1 2027; ENTR-601-45 Cohort 1 data expected October 2026
Risk Factors
- No explicit new or changed risk factor identified; provided excerpt is a standard carried-forward disclosure
- Liquidity risk: cash, equivalents, and marketable securities expected to fund operations into third quarter of 2027
- Financing risk: $150.0 million at-the-market offering may not produce sales at acceptable prices
- Clinical concentration risk: ENTR-601-44 failure could diminish EEV Platform value and harm development plans
- Profitability risk: accumulated deficit reached $355.6 million as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Entrada Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.